His main research concerns Psychiatry, Mental health, Public health, Veterans Affairs and Clinical psychology. His research related to Substance abuse, Schizophrenia, Antipsychotic, Mental illness and Anxiety disorder might be considered part of Psychiatry. In his research on the topic of Mental health, Specialty is strongly related with Health care.
His Public health study combines topics from a wide range of disciplines, such as National Health Interview Survey and Mental health treatment. His study in Veterans Affairs is interdisciplinary in nature, drawing from both Patient satisfaction, Distress and Diagnosis of schizophrenia. His Clinical psychology study combines topics from a wide range of disciplines, such as Psychosocial, Rehabilitation, Caregiver burden and Comorbidity.
Robert A. Rosenheck mainly investigates Psychiatry, Mental health, Veterans Affairs, Public health and Substance abuse. His Psychiatry research incorporates elements of Health care and Clinical psychology. Robert A. Rosenheck combines subjects such as Logistic regression, Gerontology, Family medicine, Specialty and Medical prescription with his study of Mental health.
His research integrates issues of Psychosis and Quality of life in his study of Schizophrenia. His Antipsychotic research integrates issues from Risperidone and Internal medicine, Randomized controlled trial. His study looks at the relationship between Risperidone and fields such as Olanzapine, as well as how they intersect with chemical problems.
Robert A. Rosenheck mostly deals with Psychiatry, Mental health, Mental illness, Substance abuse and Family medicine. His research in Psychiatry intersects with topics in Medical prescription and Logistic regression. Robert A. Rosenheck has included themes like Health care, Disease, Public health and Specialty in his Mental health study.
His work in Health care addresses issues such as Veterans Affairs, which are connected to fields such as Psychosocial. His work carried out in the field of Mental illness brings together such families of science as Biopsychosocial model, Stigma, Social determinants of health and Clinical psychology. His study explores the link between Substance abuse and topics such as Schizophrenia that cross with problems in Psychosis, Randomized controlled trial and Young adult.
Robert A. Rosenheck focuses on Psychiatry, Mental health, Opioid use disorder, Medical prescription and Schizophrenia. His work in the fields of Substance abuse, Mental illness, Antipsychotic and Major depressive disorder overlaps with other areas such as Alcohol use disorder. He has researched Major depressive disorder in several fields, including Quetiapine, Aripiprazole, Olanzapine, Risperidone and Pharmacoepidemiology.
His Mental health research is multidisciplinary, relying on both Quality of life, Disease and Comorbidity. The concepts of his Medical prescription study are interwoven with issues in Family medicine, Ambulatory, Depression and Fibromyalgia. His Schizophrenia research is multidisciplinary, incorporating elements of Bipolar disorder, Randomized controlled trial, Psychological resilience, Cognitive test and Neurocognitive.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz.
The New England Journal of Medicine (2005)
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis.
American Journal of Psychiatry (2006)
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Michael J. Sernyak;Douglas L. Leslie;Renato D. Alarcon;Miklos F. Losonczy.
American Journal of Psychiatry (2002)
Compliance With Medication Regimens for Mental and Physical Disorders
Joyce A. Cramer;Robert Rosenheck.
Psychiatric Services (1998)
A National Study of Violent Behavior in Persons With Schizophrenia
Jeffrey W. Swanson;Marvin S. Swartz;Richard A. Van Dorn;Eric B. Elbogen.
Archives of General Psychiatry (2006)
Naltrexone in the treatment of alcohol dependence.
John H. Krystal;Joyce A. Cramer;William F. Krol;Gail F. Kirk.
The New England Journal of Medicine (2001)
Consensus criteria for traumatic grief: A preliminary empirical test
Holly G. Prigerson;M. K. Shear;S. C. Jacobs;C. F. Reynolds.
British Journal of Psychiatry (1999)
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Robert Rosenheck;Joyce Cramer;Weichun Xu;Jonathan Thomas.
The New England Journal of Medicine (1997)
Stigma as a barrier to recovery: Adverse effects of perceived stigma on social adaptation of persons diagnosed with bipolar affective disorder.
Deborah A. Perlick;Robert A. Rosenheck;John F. Clarkin;Jo Anne Sirey.
Psychiatric Services (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: